Benefits of Incorporating Fusion-Guided Biopsy into Practice

Firas F. Abdollah, MD, provides insights on how MRI- or fusion-guided technologies are used with transrectal and transperineal biopsy procedures and how they improve traditional biopsy procedures.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.The Role of Imaging in Diagnosing and Staging Prostate Cancer

EP: 2.Advances in Prostate Biopsy

Now Viewing

EP: 3.Benefits of Incorporating Fusion-Guided Biopsy into Practice

EP: 4.A Review of the Data for Fusion-Based Biopsy Procedures

EP: 5.Understanding Differences in Fusion-Guided Biopsy Technologies

EP: 6.The Role for Systematic Biopsy Plus MRI-Targeted Procedures

EP: 7.Fusion-Guided Biopsies in Active Surveillance for Patients With Prostate Cancer

EP: 8.Using Fusion-Guided Biopsy to Determine Eligibility for Focal Therapy

EP: 9.Incorporating Fusion-Guided Biopsy to Practice

EP: 10.Future Directions for Imaging and Biopsy in Prostate Cancer

EP: 11.The Impact of MRI-Guided Biopsy in Diagnosis and Treatment Decisions

EP: 12.Overcoming Limitations of Traditional Biopsies with MRI-Guided Biopsies

EP: 13.An Overview of Fusion-Guided Systems

EP: 14.Fusion-Based Biopsies in Active Surveillance

EP: 15.Expert Insights on MRI-US Fusion-Guided Biopsy

EP: 16.The Impact of Fusion-Guided Biopsy on Focal Therapy in Prostate Cancer

EP: 17.Looking Ahead: Image-Guided Diagnostic Tools

Related Videos

Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape

An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer

Rana McKay, MD, on the role of radium-223 in the modern era

Dr Louise Kostos discusses PSA kinetics in mHSPC

Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC

The importance of PSADT in high-risk, biochemically recurrent prostate cancer

Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC

Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer

Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation

Dr Louise Kostos discusses combination therapies in mHSPC

Related Content

Advertisement

March 28th 2025

FDA approves expanded label for 177Lu-PSMA-617 in mCRPC

Hannah Clarke

The approval is supported by positive data from the phase 3 PSMAfore trial.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke

Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.

March 17th 2025

Exercise may improve erectile function in men with prostate cancer

Hannah Clarke

“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.

Related Content

Prostate CancerViewpointsThe Role of Fusion-Guided Biopsy in the Management of Prostate CancerUCI HealthCleveland Clinic

Prostate Cancer

|

Viewpoints

|

The Role of Fusion-Guided Biopsy in the Management of Prostate Cancer

|

UCI Health

|

Cleveland Clinic

Advertisement

March 28th 2025

FDA approves expanded label for 177Lu-PSMA-617 in mCRPC

Hannah Clarke

The approval is supported by positive data from the phase 3 PSMAfore trial.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 22nd 2025

Data reinforce isodose MHFRT as standard of care radiotherapy regimen

Hannah Clarke

“These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

March 20th 2025

Trial launches of CBP/p300 inhibitor in mCRPC

Hannah Clarke

Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.

March 17th 2025

Exercise may improve erectile function in men with prostate cancer

Hannah Clarke

“The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.